949 related articles for article (PubMed ID: 27920336)
1. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
2. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
3. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
4. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
5. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
6. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
[TBL] [Abstract][Full Text] [Related]
7. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
8. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
9. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
[TBL] [Abstract][Full Text] [Related]
10. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
11. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
[TBL] [Abstract][Full Text] [Related]
12. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
13. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
14. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR
Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
17. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
Aghdashi MA; Khadir M; Dinparasti-Saleh R
Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
[TBL] [Abstract][Full Text] [Related]
18. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
[TBL] [Abstract][Full Text] [Related]
19. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
20. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]